Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

METHACRYLIC ACID-ETHYL ACRYLATE COPOLYMER (1:1) - TYPE A CRS

METHACRYLIC ACID-ETHYL ACRYLATE COPOLYMER (1:1) - TYPE A CRS

NA

DISCOVER
PERINDOPRIL FOR PEAK IDENTIFICATION CRS (5 MG)

PERINDOPRIL FOR PEAK IDENTIFICATION CRS (5 MG)

107133-36-8

DISCOVER
MOXIDECTIN CRS (70 MG)

MOXIDECTIN CRS (70 MG)

113507-06-5

DISCOVER
LANSOPRAZOLE CRS (60 MG)

LANSOPRAZOLE CRS (60 MG)

103577-45-3

DISCOVER
LANSOPRAZOLE FOR PEAK IDENTIFICATION CRS (1.01 MG)

LANSOPRAZOLE FOR PEAK IDENTIFICATION CRS (1.01 MG)

103577-45-3

DISCOVER
BENZBROMARONE CRS (10 MG)

BENZBROMARONE CRS (10 MG)

3562-84-3

DISCOVER
METHYLERGOMETRINE MALEATE CRS(10 MG)

METHYLERGOMETRINE MALEATE CRS(10 MG)

57432-61-8

DISCOVER
METHYLERGOMETRINE FOR SYSTEM SUITABILITY CRS (0.53 MG)

METHYLERGOMETRINE FOR SYSTEM SUITABILITY CRS (0.53 MG)

57432-61-8

DISCOVER
WARFARIN SODIUM CLATHRATE CRS(10 MG)

WARFARIN SODIUM CLATHRATE CRS(10 MG)

NA

DISCOVER
Chlortalidone for peak identification

Chlortalidone for peak identification

77-36-1

DISCOVER
PARAFFIN (HARD) CRS (10 MG)

PARAFFIN (HARD) CRS (10 MG)

8002-74-2

DISCOVER
FOSFOMYCIN CALCIUM CRS (15 MG)

FOSFOMYCIN CALCIUM CRS (15 MG)

26469-67-0

DISCOVER